Stock SYRS SYROS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Syros Pharmaceuticals, Inc.

Equities

SYRS

US87184Q2066

Market Closed - Nasdaq
Other stock markets
 21:00:00 08/05/2024 BST 		5-day change 1st Jan Change
5 USD -2.91% Intraday chart for Syros Pharmaceuticals, Inc. -8.09% -35.82%
04-09 Sector Update: Health Care Stocks Mixed in Late Afternoon Trading MT
04-09 Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Syros to Participate in Upcoming Investor Conferences
BU
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
BU
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
BU
Syros Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
BU
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
BU
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
BU
Syros to Participate in TD Cowen 44th Annual Health Care Conference
BU
Thinking about buying stock in Applied UV, Crowdstrike, Syros Pharmaceuticals, Captivision, or Polestar Automotive?
PR
Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
BU
Thinking about buying stock in NGM Biopharmaceuticals, Syros Pharmaceuticals, Mereo BioPharma, BTCS Inc, or Sentage Holdings?
PR
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
BU
Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
BU
Syros to Participate in Upcoming Investor Conferences
BU
Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
BU
Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
BU
Syros Pharmaceuticals : Costs Associated with Exit/Disposal - Form 8-K
PU
Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company
BU
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SYRS Stock
  4. News Syros Pharmaceuticals, Inc.
  5. Press Releases